The blood cancer drug ibrutinib causes hypertension more often than previously thought, potentially leading to other cardiovascular problems, doctors warned yesterday.
The problem can be effectively treated with anti-hypertensive drugs, according to the US researchers.
The study, reported in the journal Blood, found that within six months more than half of patients prescribed the drug developed new or worsened hypertension. There was also an increased risk of atrial fibrillation, researchers at the Ohio State University, USA, found.
The single-centre study involved 562 patients with an average age of 64, treated with the drug for B-cell cancers over an eight-year period.
Nearly 72% were newly diagnosed with hypertension...
6 days ago
The blood cancer drug ibrutinib causes hypertension more often than previously thought, potentially leading to other cardiovascular problems, doctors warned yesterday.
The problem can be effectively treated with anti-hypertensive...
6 days ago
Two interacting faulty genes may play a key role in the development of acute myeloid leukaemia (AML) in some patients, British researchers have reported.
Both genes are currently the target of drugs under development. The researc...
6 days ago